Influenza infection in human host: challenges in making a better influenza vaccine
- PMID: 26885890
- DOI: 10.1586/14787210.2016.1155450
Influenza infection in human host: challenges in making a better influenza vaccine
Abstract
Influenza is a ubiquitous infection with a spectrum ranging from mild to severe. The mystery regarding such variability in the clinical spectrum has not been fully unravelled, although a role for the complex interplay among virus characteristics, host immune response and environmental factors has been suggested. Antivirals and current vaccines have a limited role in prophylaxis and treatment because they primarily target surface glycoproteins which undergo antigenic/genetic changes under host immune pressure. Targeting conserved internal proteins could lead the way to a universal vaccine which can be used against various types/subtypes. However, this is on the distant horizon, so in the meantime, developing improved vaccines should be given high priority. In this review, we discuss where the current influenza research stands in terms of vaccines, adjuvants, and how we can better predict the vaccine strains for upcoming influenza seasons by understanding complex phenomena which drive the continuous antigenic evolution.
Keywords: Influenza; adaptive immune response; adjuvants; antigenic evolution; antigenic sites; heterosubtypic immunity; influenza proteins; innate immune response; universal vaccine; vaccine mismatch.
Similar articles
-
The evolution of seasonal influenza viruses.Nat Rev Microbiol. 2018 Jan;16(1):47-60. doi: 10.1038/nrmicro.2017.118. Epub 2017 Oct 30. Nat Rev Microbiol. 2018. PMID: 29081496 Review.
-
[Research progress and prospect of universal influenza vaccine].Bing Du Xue Bao. 2013 Nov;29(6):646-50. Bing Du Xue Bao. 2013. PMID: 24520771 Review. Chinese.
-
Toward a universal influenza virus vaccine: prospects and challenges.Annu Rev Med. 2013;64:189-202. doi: 10.1146/annurev-med-120611-145115. Annu Rev Med. 2013. PMID: 23327522 Review.
-
Influenza vaccines: what do we want and how can we get it?Adv Exp Med Biol. 2011;780:161-74. doi: 10.1007/978-1-4419-5632-3_13. Adv Exp Med Biol. 2011. PMID: 21842372 Review.
-
Influenza Virus: Dealing with a Drifting and Shifting Pathogen.Viral Immunol. 2018 Mar;31(2):174-183. doi: 10.1089/vim.2017.0141. Epub 2018 Jan 26. Viral Immunol. 2018. PMID: 29373086 Review.
Cited by
-
ATP catabolism by tissue nonspecific alkaline phosphatase contributes to development of ARDS in influenza-infected mice.Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L83-L92. doi: 10.1152/ajplung.00149.2017. Epub 2017 Oct 5. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 28982733 Free PMC article.
-
A universal mammalian vaccine cell line substrate.PLoS One. 2017 Nov 27;12(11):e0188333. doi: 10.1371/journal.pone.0188333. eCollection 2017. PLoS One. 2017. PMID: 29176782 Free PMC article.
-
Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.Hum Vaccin Immunother. 2018 Mar 4;14(3):508-517. doi: 10.1080/21645515.2017.1377871. Epub 2017 Nov 17. Hum Vaccin Immunother. 2018. PMID: 29048990 Free PMC article.
-
Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets.NPJ Vaccines. 2021 Apr 21;6(1):59. doi: 10.1038/s41541-021-00320-9. NPJ Vaccines. 2021. PMID: 33883559 Free PMC article.
-
MASS SPECTROMETRY IN VIROLOGICAL SCIENCES.Mass Spectrom Rev. 2020 Sep;39(5-6):499-522. doi: 10.1002/mas.21617. Epub 2019 Dec 25. Mass Spectrom Rev. 2020. PMID: 31876329 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical